Transgenic mice expressing the catalytic subunit of PKA in the heart developed dilated cardiomyopathy, reduced contractility, arrhythmias, and susceptibility to sudden death.
beta-Adrenergic receptor (betaAR) signaling, which elevates intracellular cAMP and enhances cardiac contractility, is severely impaired in the failing heart. Protein kinase A (PKA) is activated by cAMP, but the long-term physiological effect of PKA activation on cardiac function is unclear. To investigate the consequences of chronic cardiac PKA activation in the absence of upstream events associated with betaAR signaling, we generated transgenic mice that expressed the catalytic subunit of PKA in the heart. These mice developed dilated cardiomyopathy with reduced cardiac contractility, arrhythmias, and susceptibility to sudden death. As seen in human heart failure, these abnormalities correlated with PKA-mediated hyperphosphorylation of the cardiac ryanodine receptor/Ca(2+)-release channel, which enhances Ca(2+) release from the sarcoplasmic reticulum, and phospholamban, which regulates the sarcoplasmic reticulum Ca(2+)-ATPase. These findings demonstrate a specific role for PKA in the pathogenesis of heart failure, independent of more proximal events in betaAR signaling, and support the notion that PKA activity is involved in the adverse effects of chronic betaAR signaling.
Antos et al. (Fri,) conducted a other in Dilated cardiomyopathy and heart failure. Expression of the catalytic subunit of PKA in the heart was evaluated on Development of dilated cardiomyopathy, reduced cardiac contractility, arrhythmias, and sudden death. Transgenic mice expressing the catalytic subunit of PKA in the heart developed dilated cardiomyopathy, reduced contractility, arrhythmias, and susceptibility to sudden death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: